We asked some of the leading HIV experts and advocates what they would tell the next U.S. president to do in order to keep advancing the fight against HIV.
The biggest problem is disparity in access to health care, panelists agreed. This stems in part from a lack of insurance and inadequate health care facilities in communities of color.
A study presented at CROI 2016 revealed that proper support can lead to high acceptance and adherence to pre-exposure prophylaxis (PrEP) among young black men who have sex with men (MSM).
Follow-up studies, including an open-label extension, on the dapivirine vaginal ring look to build on the initial modest results of 27% overall reduction in HIV transmission.
Future PrEP might include slow release removable depots and once-a-year dosing -- and the challenge for how to quickly, safely and ethically study new PrEP drugs.
Although the CCR5 inhibitor maraviroc is largely underused as an antiretroviral drug, several studies looking at whether it has a role as PrEP seem to support use in combinations.
Data on the new version of tenofovir suggest it is very effective in animal studies but unanswered questions remain about drug levels in humans.
"The ring has the potential to help make a difference in reducing the burden of HIV by at least one third in women overall," writes Thesla Palanee-Phillips. "This has significant implications for reducing the burden of disease in women in Africa."...
"One chooses whether to focus on the glass 99% full or 1% empty. Very rarely, PrEP with FTC/TDF may fail to provide full protection against rare multidrug resistant viruses," explains Dr. Grant. "If that happens, HIV treatment is highly effective."...
While the vaginal ring's overall effectiveness of 27% doesn't sound like something to get excited about, these initial results offer a proof of concept for preventing HIV in women, with hope of future open-label extension studies revealing much highe...